Ardana PLC 16 June 2005 ARDANA SIGNS AGREEMENT WITH CYTOCHEMIA TO MARKET STRIANT(TM) SR IN GERMANY Edinburgh, UK, 16 June 2005; Ardana plc (LSE:ARA) the emerging pharmaceutical company focused on improving human reproductive health, today announces that it has signed an agreement under which Ardana grants Cytochemia AG exclusive rights to market Striant(TM) SR in Germany. Striant(TM) SR is a mucoadhesive buccal (gum surface) testosterone replacement therapy for primary and secondary male hypogonadism (i.e. those suffering from a deficiency or absence of testosterone). Striant(TM) SR is the first-to-market buccal adhesive tablet and is marketed by Ardana's own sales force in the UK, to urologists and endocrinologists. Cytochemia has considerable experience in Germany selling to the same specialists through their targeted sales force which has a strong track record in the education of physicians on product usage. Cytochemia has a strong complementary portfolio to Ardana and its product ImmuCyst, which has been on the market for 13 years, is an established agent for the treatment and prevention of superficial bladder cancer. Striant(TM) SR presents an excellent strategic fit with Cytochemia's product portfolio and will be an important addition. Cytochemia expects to launch Striant(TM) SR in the German market later this year. Financial terms were not disclosed but Ardana will receive an upfront payment and ongoing revenues for the supply of Striant(TM)SR to Cytochemia. Dr. Maureen Lindsay, Chief Executive of Ardana, said: "As the biggest and most developed market in Europe for testosterone replacement, Germany is key for Striant(TM) SR. In partnering with Cytochemia we believe that the product is in the best hands to ensure a successful introduction there. Striant's novel and efficient delivery of testosterone has received high levels of acceptance from both patients and prescribers." For more information contact: Ardana Financial Dynamics Maureen Lindsay (corporate/financial media relations) Tel: + 44 (0) 131 226 8550 Julia Phillips/Davina Langdale Tel: +44 (0)20 7831 3113 NB Public Relations (trade/technical media relations) Nicki Brimicombe Tel: + 44 (0)1883 732353 About Ardana Ardana plc is a pharmaceutical company focused on the discovery, development and marketing of innovative products to improve human reproductive health, a $23.8 billion market. Since its foundation, Ardana has maintained a broad and balanced portfolio to manage risk and actively pursues product and technology in-licensing and out-licensing to maintain a robust pipeline. Ardana's four lead products are summarised below: • Striant(TM) SR, a testosterone replacement therapy that has already been launched by Ardana through its own sales force in the UK as a treatment for men with hypogonadism and for which Ardana has marketing rights in Europe; • Teverelix LA, in development for three initial indications (prostate cancer, benign prostatic hyperplasia and endometriosis); • Testo Bi-gel, a trans dermal testosterone delivery system in development for the treatment of male hypogonadism, shortly to enter Phase II trials; • Invicorp, an injectable combination drug treatment for erectile dysfunction, for which Ardana has marketing and manufacturing rights in Europe. In addition, Ardana has a strong portfolio of follow-on products in development. Ardana completed its IPO on the London Stock Exchange in March 2005 raising £21 million. For further information please see www.ardana.co.uk Cytochemia Cytochemia is an independent pharmaceutical company based in Germany specializing in immuno-therapeutics from either their own product development or exclusive licence agreements. The target group for Cytochemia's therapeutics consists of gynaecologists, oncologists and urologists. The company is primarily active in the German market but in 2000 the company founded another branch of the business in Switzerland. This information is provided by RNS The company news service from the London Stock Exchange